By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit, LinkedIn and follow us on


Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 20,000
Symbol: AMGN

Company News
Amgen (AMGN)’s Backup Plan For Kyprolis Flop 9/30/2016 7:17:33 AM
Amgen (AMGN) Maintains Migraine Drug Lead 9/30/2016 7:15:04 AM
SoCal's Arrowhead Pharma (ARWR) Just Snagged a $673.5 Million Heart Deal With Amgen (AMGN) 9/29/2016 6:04:05 AM
Amgen (AMGN), Novartis AG (NVS)'s Migraine Drug Successful in Phase III Study 9/29/2016 5:43:51 AM
Amgen (AMGN) And UCB Group (UCBJF.PK) Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab 9/27/2016 6:56:37 AM
Amgen (AMGN) Hit With a Setback as Krypolis Fails to Help Newly Diagnosed Multiple Myeloma Patients 9/27/2016 5:49:32 AM
Amgen (AMGN) Waves Golden Tickets at Biotech Startups for Kendall Square Space 9/26/2016 3:51:51 PM
FDA Clears Amgen (AMGN) Copy of AbbVie (ABBV)'s Blockbuster Humira 9/26/2016 5:49:14 AM
Another Good Day for Amgen (AMGN) as Repatha Phase III GLAGOV Trial Met Primary, Secondary Endpoints 9/20/2016 7:24:19 AM
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Showed Significant Results in Phase III Study 9/19/2016 5:52:37 AM